Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction notification and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction by Mr. S M Bicknell, a person discharging managerial responsibility. On January 7, 2013, he acquired a beneficial interest in 11 Ordinary Shares through the re-investment of dividends under Personal Equity Plans at a price of 1373.5 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) for reporting insider transactions.
Key Facts for Investor Verification
- Transaction Date: January 7, 2013.
- Individual: Mr. S M Bicknell (Person Discharging Managerial Responsibility).
- Transaction Type: Acquisition of 11 Ordinary Shares via dividend re-investment.
- Share Price: 1373.5 pence per share.
- Notification Date: January 8, 2013.